

Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases.

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops, and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, Regeneron's unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in Regeneron's laboratories. Regeneron's medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as *VelociSuite*®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.

For more information, please visit www.Regeneron.com or follow Regeneron on [LinkedIn](#), [Instagram](#), [Facebook](#) or [X](#).

General Company Information




- Founded in 1988: Publicly traded company (NASDAQ: REGN) since 1991
- More than 14,000 employees in the U.S., Canada, UK, EU and Asia
- 2023 R&D investment of \$4.4 billion

Locations



- Tarrytown, NY: Corporate and Research & Development headquarters
- Dublin, Ireland: European headquarters
- Rensselaer, NY and Limerick, Ireland: Industrial Operations and Product Supply facilities
- U.S. offices in New York, New Jersey, Washington, D.C., Massachusetts and California
- Global offices in Canada, Netherlands, United Kingdom, Germany, France, Italy, Spain, Switzerland, India, Japan

Leadership Team



- **Leonard S. Schleifer, MD, PhD**
co-Founder, Board co-Chair, President and Chief Executive Officer
+ *Fellow, American Association for the Advancement of Science (AAAS)*
- **George D. Yancopoulos, MD, PhD**
co-Founder, Board co-Chair, President and Chief Scientific Officer
+ *Member, National Academy of Sciences*
- **Christine A. Poon**
Lead Independent Director
Former Vice Chair, Worldwide Chair of Pharmaceuticals, Member of the Executive Committee and Director at Johnson & Johnson
- **Board of Directors** includes two Nobel Laureates and six members of the National Academy of Sciences

FDA-Approved & Marketed Medicines*



1 Commercialized by Kiniksa Pharmaceuticals, Ltd. 2 Commercialized with Sanofi. 3 Commercialized by Regeneron in the United States and Ultragenyx Pharmaceuticals Inc. outside the United States. 4 Commercialized by Regeneron in the United States and Bayer outside the United States. 5 Commercialized by Regeneron in the United States and Sanofi outside the United States. 6 Commercialized by Sanofi.

Clinical Product Candidates

PHASE 1

ALN-HTT02

RNAi therapeutic targeting HTT
Huntington's disease

ALN-SOD*

RNAi therapeutic targeting SOD1
SOD1 amyotrophic lateral sclerosis (ALS)

MIVELSIRAN

RNAi therapeutic targeting APP
Early-onset Alzheimer's disease

ALN-PNP

RNAi therapeutic targeting PNPLA3
Non-Alcoholic Fatty Liver Disease (NAFLD)

DB-OTO

AAV-based gene therapy
Hearing loss in pediatrics (Phase 1/2)

DUPILUMAB/LINVOSELTAMAB

Antibody to IL-4R / Bispecific antibody
targeting BCMA and CD3 | Severe food allergy

FIANLIMAB

Antibody to LAG-3 | Solid tumors,
advanced hematologic malignancies

NEXIGURAN ZICLUMERAN (NTLA-2001)

TTR gene knockout using CRISPR/Cas9
Transferrin amyloidosis with
Polyneuropathy (ATTR-PN)

ODRONEXTAMAB

Bispecific antibody targeting CD20 and CD3
Certain B-cell malignancies

27T51

Cell therapy targeting MUC16
Ovarian cancer

REGN4336

Bispecific antibody targeting PSMA and CD3
Prostate cancer

REGN5093-M114

Bispecific antibody-drug conjugate targeting
two distinct MET epitopes
MET overexpressing
advanced cancer

REGN9035

Agonist Antibody to NPR1/Reversal
Agent to REGN5381 | NPR1

LINVOSELTAMAB

Bispecific antibody targeting BCMA and CD3
Multiple myeloma

VONSETAMIG (REGN5459)

Bispecific antibody targeting BCMA and CD3
Transplant desensitization in patients
with chronic kidney disease

REGN10597

Bispecific antibody targeting PD1-IL2Ra
Solid tumors (Phase 1/2)

REGN5668

Bispecific antibody targeting MUC16 and CD28
Platinum-resistant ovarian cancer

NEZASTOMIG (REGN5678)

Bispecific antibody targeting PSMA and CD28
Renal cell carcinoma

NEZASTOMIG (REGN5678)/ REGN4336

Bispecific antibody targeting PSMA and CD28 /
PSMA and CD3 combo | Prostate cancer

REGV131-LNP1265

Factor 9 | Hemophilia B

REGN5837

Bispecific antibody targeting CD22 and CD28
B-NHL

Next Generation Covid Antibody

Antibody to SARS-CoV-2 Variants
SARS-CoV-2 Variants

REGN7544

Antagonist antibody to NPR1 | Healthy volunteers

REGN13335

Antagonist antibody to PDGF-b | Healthy volunteers

ALN-ANG3

RNAi therapeutic targeting ANGPTL3
Chronic kidney disease

PHASE 2

REGN7075

Bispecific antibody targeting
EGFR and CD28 | Solid tumors

ITEPEKIMAB

Antibody to IL-33
Non-cystic fibrosis
bronchiectasis (NCFB)

NEZASTOMIG (REGN5678)

Bispecific antibody targeting
PSMA and CD28 | Prostate cancer

TREVOGRUMAB (REGN1033)

Antibody to Myostatin (GDF8)
Obesity

RAPIROSIRAN (ALN-HSD)

RNAi therapeutic targeting
HSD17B13 | Metabolic dysfunction-
associated steatohepatitis (MASH)

CEMIPLIMAB

Antibody to PD-1 | Neoadjuvant
cutaneous squamous cell
carcinoma (CSCC); First-line
non-small cell lung cancer
(NSCLC), BNT116 combination;
Neoadjuvant NSCLC; Neoadjuvant
hepatocellular carcinoma (HCC)

DUPILUMAB

Antibody to IL-4R alpha subunit
Ulcerative colitis; Eosinophilic
gastroenteritis (Phase 2/3)

ODRONEXTAMAB

Bispecific antibody targeting
CD20 and CD3
B-cell non-Hodgkin lymphoma
(B-NHL) (pivotal study)

DAVUTAMIG

Bispecific antibody targeting
two distinct MET epitopes
MET-altered advanced non-small
cell lung cancer (NSCLC)

FIANLIMAB

Antibody to LAG-3
First-line advanced non-small cell
lung cancer (NSCLC) (Phase 2/3);
Perioperative NSCLC; Perioperative
melanoma (Phase 2/3)

MIBAVADEMAB

Agonist antibody to leptin
receptor (LEPR)
Generalized lipodystrophy

REGN5381

Agonist antibody to NPR1
Heart failure

LINVOSELTAMAB

Bispecific antibody targeting
BCMA and CD3 | Multiple myeloma
(pivotal study); Earlier (pre-malignant)
multiple myeloma; Monoclonal
gammopathy of undetermined
significance (MGUS); Light chain
amyloidosis (ALA)

SARILUMAB

Antibody to IL-6R
Systemic juvenile idiopathic arthritis
(sJIA) (pivotal study)

UBAMATAMAB

Bispecific antibody targeting
MUC16 and CD3
Platinum-resistant ovarian cancer

REGN9933

Antibody to Factor XI
Thrombosis

REGN7508

Antibody to Factor XI | Thrombosis

REGN7257

Antibody to IL2Rg | Aplastic anemia

REGN7999

Antibody to Tmprss6
Transfusion dependent iron overload

PHASE 3

EYLEA HD (AFLIBERCEPT) 8 MG

VEGF | Retinal vein occlusion (RVO)

CEMIPLIMAB

Antibody to PD-1 | Adjuvant CSCC

DUPILUMAB

IL-4R Alpha Subunit Antibody
Asthma in pediatrics (2-5 years of age);
bullous pemphigoid; chronic spontaneous
urticaria (CSU); chronic pruritis of unknown
origin (CPUO)

FIANLIMAB

Antibody to LAG-3
First-line metastatic melanoma; Adjuvant
melanoma; First-line metastatic melanoma
versus the combination of relatlimab and
nivolumab

ITEPEKIMAB

IL-33 Antibody | COPD

NEXIGURAN ZICLUMERAN (NTLA-2001)

TTR gene knockout using CRISPR/Cas9
Transferrin amyloidosis with
cardiomyopathy (ATTR-CM)

POZELIMAB

C5 | Myasthenia gravis, cemisdiran
combination; paroxysmal nocturnal
hemoglobinuria (PNH), cemisdiran
combination; Geographic atrophy,
cemisdiran combination

REGN5713-5714-5715

Multi-antibody therapy to Bet v 1
Birch allergy

GARETOSMAB

Antibody to Activin A
Fibrodysplasia ossificans
progressiva (FOP)

LINVOSELTAMAB

BCMA and CD3 | Multiple myeloma

ODRONEXTAMAB

CD20 and CD3 | Follicular lymphoma (FL);
Diffuse large B-cell lymphoma (DLBCL)

In collaboration with: ① Sanofi | ② Bayer | ③ Intellia | ④ Alnylam *on U.S. FDA clinical hold; enrolling ex-U.S.

■ Ophthalmology ■ Infectious Diseases ■ Immunology & Inflammatory Diseases ■ Oncology ■ Cardiovascular/Metabolic Diseases ■ Hematology ■ Rare Diseases ■ Neurology

This graphic displays pipeline drug candidates currently undergoing clinical testing in a variety of diseases.

The safety and efficacy of these drug candidates have not been fully evaluated by any regulatory authorities for the indications described in this section.

Leaders in Technology

Fully human monoclonal antibodies

Regeneron has developed a suite of patented technologies (*VelociSuite*®), including *VelociGene*®, *VelocImmune*® and *VelociMab*®, that allow Regeneron scientists to determine the best targets for therapeutic intervention and rapidly generate high quality, fully human antibodies as drug candidates.

Regeneron Genetics Center®

A large-scale, fully-integrated genomics program that uses DNA sequencing and analysis to better understand the causes of disease, and to more rapidly and efficiently bring new therapeutics to patients in need.

Genetic Medicines technology

We've made significant strides by leveraging our long-standing leadership in antibody technologies, combined with insights from the Regeneron Genetics Center® to build a pipeline of genetic medicine spanning multiple therapeutic approaches, including gene silencing, editing and gene therapy. With multiple genetic medicines-based technologies at our fingertips, we now have the potential to address the most promising genetic targets, driving forward scientific progress to change lives.

Science: Top Employer, 2024

TIME: World's Most Sustainable Companies, 2024

US News & World Report: Best Companies to Work for, 2024

IDEA Pharma: Top 10 Pharmaceutical Innovation/Invention Index, 2024

Newsweek: America's Most Responsible Companies, 2024

Newsweek: America's Greatest Workplaces for Diversity, 2024



Biospace: Best Place to Work, 2024

Disability: IN & American Association of People with Disabilities:
Best Place to Work for Disability Inclusion, 2024

LexisNexis: Innovation Momentum – The Global Top 100, 2024

Civic 50: Most Community-Minded Companies in the Nation, 2024

Dow Jones Sustainability World & North America Index, 2023